Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Topica Pharmaceuticals has entered into a sublicense and purchase option agreement with an undisclosed partner to develop Luliconazole exclusively for tinea infections of the skin in the Americas and Europe.
Subscribe to our email newsletter
In conjunction with the sublicensing agreement, Topica Pharmaceuticals will now focus on developing Luliconazole exclusively for the treatment of onychomycosis.
Reportedly, in February of 2010 the company’s IND for onychomycosis was opened, paving the way for human clinical trials to begin later in 2010.
Topica Pharma president and CEO Greg Vontz they are looking forward to the initiation of Luliconazole’s clinical development program this fall and validating the molecule’s promising preclinical profile in onychomycosis.
“If the molecule’s preclinical profile is validated, Luliconazole has the potential to be the first truly effective, safe and convenient topical therapy for onychomycosis; providing physicians and patients with a much needed alternative to currently available oral anti-fungal therapies that have risk of serious adverse events, Vontz said.